Novel concepts for HIV vaccine vector design

Quazim A. Alayo, Nicholas M. Provine, Pablo Penaloza-MacMaster*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations


The unprecedented challenges of developing effective vaccines against intracellular pathogens such as HIV, malaria, and tuberculosis have resulted in more rational approaches to vaccine development. Apart from the recent advances in the design and selection of improved epitopes and adjuvants, there are also ongoing efforts to optimize delivery platforms. Viral vectors are the best-characterized delivery tools because of their intrinsic adjuvant capability, unique cellular tropism, and ability to trigger robust adaptive immune responses. However, a known limitation of viral vectors is preexisting immunity, and ongoing efforts are aimed at developing novel vector platforms with lower seroprevalence. It is also becoming increasingly clear that different vectors, even those derived from phylogenetically similar viruses, can elicit substantially distinct immune responses, in terms of quantity, quality, and location, which can ultimately affect immune protection. This review provides a summary of the status of viral vector development for HIV vaccines, with a particular focus on novel viral vectors and the types of adaptive immune responses that they induce.

Original languageEnglish (US)
Article numbere00415-17
Issue number6
StatePublished - Nov 1 2017


  • Antibodies
  • Human immunodeficiency virus
  • T cells
  • Vaccines

ASJC Scopus subject areas

  • Molecular Biology
  • Microbiology


Dive into the research topics of 'Novel concepts for HIV vaccine vector design'. Together they form a unique fingerprint.

Cite this